TY - JOUR AU - Hussain, Dr. Muhammad AU - Bashir, Muhammad Mukarram AU - Tipu, Hamid Nawaz AU - Dawood, Muhammad AU - Afshan, Noor AU - Arooj, Ayesha PY - 2022/05/01 Y2 - 2024/03/29 TI - Association of Panel Reactive Antibodies (PRA) with Complement Dependent Cytotoxicity (CDC) Cross-Match in Pre-Renal Transplant Recipients JF - Pakistan Armed Forces Medical Journal JA - PAFMJ VL - 72 IS - 2 SE - Original Articles DO - 10.51253/pafmj.v72i2.4810 UR - https://pafmj.org/PAFMJ/article/view/4810 SP - 509-12 AB - <p><strong>Objective:</strong> To determine the association of panel reactive antibodies (PRA) with complement-dependent cytotoxicity (CDC) cross-match in Pakistani pre-renal transplant recipients.</p><p><strong>Study Design:</strong> Cross-sectional study.</p><p><strong>Place and Duration of Study:</strong> Immunology Department, Armed Forces Institute of Pathology, Rawalpindi from Oct 2017 to Oct 2018.</p><p><strong>Methodology:</strong> A total of 162 patients referred to the Department of Immunology for pre-transplant workup for renal transplantation were included. Informed consent was taken, and detailed history was recorded. Frequency and percentages were calculated for cross-match positivity and most frequent anti-HLA antibodies.</p><p><strong>Results:</strong> Panel reactive antibodies (PRA) were present in 48 patients (30%), while complement-dependent cytotoxicity (CDC) cross-match was positive in 16 patients (10%). Out of 141 male patients, 35 (25%) were positive for PRA, while 10 (7%) had positive CDC cross-match. Out of 21 female recipients, 13 (62%) were positive for PRA, and 6 (28%) had positive CDC crossmatch. One male patient positive for CDC cross-match was negative for PRA. Patients positive for both CDC cross-match and PRA have an average mean fluorescent intensity (MFI) of more than 4000. CDC cross-match and PRA were strongly associated, whereas no significant association was found between CDC cross-match and anti-MIC antibodies.</p><p><strong>Conclusion:</strong> Complement dependent cytotoxicity (CDC) cross-match and panel reactive antibodies (PRA) should be routine in patients undergoing renal transplants as alone CDC cross-match can give false negative or false-positive results. At the same time, CDC cross-match lacks detection of anti MIC antibodies involved in graft rejection.</p> ER -